NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.89 (-0.94%)

Growth Price

Overvalued by 31.84%

Stability Price

Overvalued by 76.75%

Company Metrics

  • P/E 11.73
  • P/S 4.4
  • P/B 2.89
  • EPS 7.96
  • Cash ROIC 12.42%
  • Cash Ratio 0.51
  • Dividend 2.67 / 2.86%
  • Avg. Vol. 1.87M
  • Shares 2.42B
  • Market Cap. 225.36B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis AG (ADR) On Collision Course With Amgen, Inc. Again With Another ...
Bidness ETC - Oct 2, 2015
Novartis AG ADR (NYSE:NVS) and Amgen Inc. (NASDAQ:AMGN) seem to be on a collision course again as Novartis is on track to get another biosimilar candidate approved by the US Food and Drug Administration (FDA).
Trade of the Day: NVS Stock Not Making the Cut – Sell Now
Investorplace.com - Oct 1, 2015
Novartis AG (ADR) (NVS) - This company is a leading provider of pharmaceuticals, generic drugs and health care products for consumers and animals.
Novartis AG (ADR) (NYSE:NVS) Plans To Provide Cheap Medicines To Poorer Countries - InvestCorrectly
Novartis AG (ADR) Partners With Amgen, Inc. On Alzheimer's And Migraine
Bidness ETC - Sep 2, 2015
Amgen, Inc. (NASDAQ:AMGN) entered into a two-way partnership deal with Novartis AG (ADR) (NYSE:NVS) on Tuesday, to co-develop the Swiss drug-maker's Alzheimer's drug pipeline, in exchange for Novartis gaining access to Amgen's migraine drug ...
Amgen, Novartis Team Up; Bone Drug Positive in Phase III - Zacks.com
Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs - Capital.gr (press release)
Novartis AG Moves Closer To EU Market With Heart Drug
Bidness ETC - Sep 28, 2015
Novartis AG ADR (NYSE:NVS) received positive feedback for its drug; Entresto (sacubitril/valsartan), from the Committee for Medicinal Products for Human Use (CHMP).
Novartis AG (ADR) (NVS) To Acquire Spinifex
Business Finance News - Jun 29, 2015
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million - Bidness ETC
Novartis to buy privately held Spinifex for $200 mln - Proactive Investors USA & Canada
Stock Report on Novartis AG (ADR) (NYSE:NVS)
Street Report - Jun 16, 2015
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Novartis AG (ADR) (NVS) Stock Update: September Begins With Multiple Deals And ...
Bidness ETC - Sep 4, 2015
Novartis AG (ADR) (NYSE:NVS) has seen an eventful first week of September. The company struck a partnership deal with biotech giant Amgen, Inc. (NASDAQ:AMGN) and won regulatory approvals for several drugs in both the US and Europe - all during the ...
Novartis AG (ADR) (NYSE:NVS) Launches Zarxio(TM) Oncology Drug - WallStreet Scope
Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds
Bidness ETC - Aug 24, 2015
Novartis AG (ADR) (NYSE:NVS) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance.
News Recap - Novartis (NVS), China Mobile (CHL), Facebook (FB), General ... - Techsonian (press release)
Amgen, Inc. Fails To Block Novartis AG (ADR) From Launching Biosimilar
Bidness ETC - Sep 3, 2015
A federal appeals court on Wednesday rejected Amgen Inc.'s (NASDAQ:AMGN) request for a temporary injunction to block Novartis AG (ADR) (NYSE:NVS) from launching a biosimilar version of Amgen's blockbuster drug, Neupogen, in the US. According to ...
Novartis to begin selling Neupogen copy in US - MarketWatch
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. - Nasdaq
Novartis AG (NVS) Stock Soars On Heart-Failure Drug Approval
Bidness ETC - Jul 8, 2015
The US Food and Drug Administration (FDA) has approved Novartis AG's (ADR) (NYSE:NVS) new heart-failure drug, Entresto, the agency announced in a press release on Tuesday.
Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog - Nasdaq
Novartis Heart Failure Drug Entresto Receives FDA Approval - Zacks.com